Hershkovitz Dov, Asna Noam, Shupak Avi, Kaminski Gil, Bar Ronen, Tal Dror
Motion Sickness and Human Performance Laboratory, Israel Naval Medical Institute, Haifa, Israel.
Aviat Space Environ Med. 2009 Jul;80(7):643-6. doi: 10.3357/asem.2365.2009.
Seasickness is a common problem, causing a significant decrement in performance among naval crew. In about 20-60% of crewmembers, symptoms appear with varying intensity depending on the sea state and the duration of the voyage. Recent studies have suggested antiemetic 5HT3 blockers as a possible treatment for motion sickness, emphasizing their minor clinical and cognitive side effects. The purpose of the present study was to evaluate the 5HT3 blocker ondansetron in the prevention of seasickness.
There were 16 volunteers with a normal otoneurologic examination and no previous medical history of inner ear disease or vertigo who took part in a double blind, randomized, crossover study. During an initial learning phase, the participants practiced on a battery of computerized performance tests until their results stabilized. Ondansetron 8 mg or placebo was administered 2 h before sailing aboard a 500-ton naval vessel in mild sea conditions. Participants did the performance tests and completed a questionnaire evaluating their seasickness symptoms 4 h into the voyage.
No statistically significant reduction of seasickness symptoms was demonstrated between ondansetron treatment and placebo (a Wiker score of 2.69 +/- 1.78 and 2.81 +/- 1.97, respectively). There was no statistically significant difference in side effects or the results of the performance tests.
In this study, ondansetron was not found to be beneficial in the treatment of seasickness. It could be speculated that the mechanism of nausea in seasickness is different from that of toxin-induced nausea.
晕船是一个常见问题，会导致海军船员的工作表现显著下降。在约20%至60%的船员中，症状会根据海况和航行持续时间出现不同程度的表现。最近的研究表明，抗呕吐5-羟色胺3（5HT3）受体阻滞剂可能是治疗晕动病的一种方法，强调了其轻微的临床和认知副作用。本研究的目的是评估5HT3受体阻滞剂昂丹司琼预防晕船的效果。
16名志愿者参与了一项双盲、随机、交叉研究，他们的耳神经学检查正常，且既往无内耳疾病或眩晕病史。在初始学习阶段，参与者进行了一系列计算机化性能测试，直到他们的结果稳定。在轻度海况下登上一艘500吨级海军舰艇航行前2小时，给予8毫克昂丹司琼或安慰剂。参与者在航行4小时后进行性能测试并完成一份评估晕船症状的问卷。
昂丹司琼治疗组和安慰剂组之间晕船症状的减轻无统计学显著差异（Wiker评分分别为2.69±1.78和2.81±1.97）。副作用或性能测试结果无统计学显著差异。
在本研究中，未发现昂丹司琼对晕船治疗有益。可以推测，晕船时恶心的机制与毒素引起的恶心机制不同。
